Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching the Zepto® Precision Pulse Capsulotomy System (“Zepto”) in Canada on June 1, 2018 during the Canadian Ophthalmological Society’s 2018 Annual Meeting and Exhibition. Aequus recently announced being appointed as the exclusive Canadian distributor for this product, under a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company based in Fremont, California (“Mynosys”).
Zepto is a novel medical device used during cataract surgery to produce a consistent, high quality, round capsulotomy in milliseconds. Zepto will be marketed by Aequus’ current ophthalmology salesforce and is an attractive complement to its existing product offering.
“We look forward to this exciting cross-Canada launch of Zepto and have already received a high level of interest from our customers to have access to this device,” said Ian Ball, Chief Commercial Officer at Aequus. “We are delighted to be able to offer this innovative tool to physicians in Canada.”
“With this launch, we have further expanded the Aequus ophthalmology team by adding key personnel with extensive experience in launching ophthalmology devices in Canada. This rounds out our team’s therapeutic experience to ensure the successful execution of this and future anticipated launches in this field,” said Doug Janzen, CEO of Aequus. “The entire team has worked tremendously hard to get this product on the market for Canadian patients and physicians as quickly as possible, and for shareholders to realize the benefits through its accretive revenues.”
About Zepto Precision Pulse Capsulotomy System
The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to allow Zepto capsulotomies on the patient’s individual visual axis. The AMA has recently given a category III code in the US as they see the distinctive application and benefit of aligning on the patient’s own visual axis.
Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine. Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.
The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely placed capsulotomy that can be centred on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates a capsulotomy with an edge strength greater than conventional methods or femtosecond lasers. For more information, please visit https://www.zepto-cataract.com/